Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of TENS Therapy for Premature Ejaculation
NCT06425224Phase 3Recruiting
- Sponsor
- Boston Medical Corporation
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (3 arms), sponsored by Boston Medical Corporation. Primary endpoint: Change in intravaginal latency time at 12 weeks. Started Jun 2022; status: recruiting.
Beyond the preview
Go deeper on NCT06425224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425224.